N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents
Obesity
Primary: Change in Insulin Resistance After 12 Weeks of Vitamin D3 Supplementation — 0.01; -0.27 HOMA score — p=0.95
Phase 1 N=157 Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
Phase 3 N=1,358 Vitamin D to Improve Outcomes by Leveraging Early Treatment
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
Phase 4 N=183 Treatment Study of Vitamin D Deficiency in Adolescents
Vitamin D Deficiency
Primary: Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D <20 ng/dL) — 6.2; 24.9; 21 ng/mL
N/A N=81 Optimizing Vitamin D in the Elderly
Deficiency of Vitamin D3
Primary: Total 25-OH Vitamin D3 Level — 33; 34; 43; 61 ng/mL — p=<.0001
Phase 3 N=265 Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina
Vitamin D Deficiency · Pregnancy
Primary: 25-hydroxyvitamin D at Visit 7 — 36.7; 39.8 ng/mL
N/A N=92 Vitamin D Deficiency, Insulin Resistance and FGF-23
Vitamin D Deficiency
Primary: Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units — 74; 39 pg/mL — p=<0.05
Phase 4 N=230 Treatment of Vitamin D Insufficiency
Vitamin D Deficiency
Primary: Intestinal Calcium Absorption — 0.200; 0.217; 0.183; 0.206 Total Fractional Calcium Absorption
Phase 2 N=57 Vitamin D3 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Percent of Participants With an IFN Alpha Signature Response at Week 12 — 36.8; 23.5; 27.8; 25.7 Percent of participants — p=0.53
N/A N=34 Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
Chronic Kidney Disease · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D — 18.6; 17.3; 19.5; 49.4 ng/mL
N/A N=125 Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus
Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg
Phase 2 N=109 Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth
Obesity · Insulin Resistance · Vitamin D Deficiency
Primary: Change in HOMA-IR — 0; -1.5; -1.7 HOMA-IR score
N/A N=96 Impact of Vitamin D Repletion in Hemodialysis Patients
Vitamin D Deficiency · End-stage Renal Disease
Primary: Change in 25OH-Vitamin D Level — 15.8; 40.9 ng/dL
Phase 2 N=550 Topical Delivery of Vitamin D3 as Vitamin D Supplementation
Vitamin D Deficiency
Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9
Phase 2 N=160 Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
Breast Cancer
Primary: Number of Participants With Worsening of Musculoskeletal Symptoms (MS) — 23; 18; 24; 18 participants
N/A N=83 Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis · Vitamin D Deficiency
Primary: Disease Activity Score (DAS) 28 — 3.4; 2.8; 3.5; 3.1 composite score
Phase 2 N=114 Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial
Prostate Cancer
Primary: Pathology Status — 2.37; 1.73 number of positive cores
N/A N=68 Improving Vitamin D Status in Home-bound Elders
Vitamin D Deficiency · Accidental Falls
Primary: Change in 25-hydroxyvitamin D Levels Over 5 Months — 21.7; 0 ng/mL
N/A N=19 Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
N/A N=43 Vitamin D Supplementation to Obese Chinese Males
Obesity · Insulin Resistance
Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L
Phase 2 N=116 Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors
Muscle Pain · Joint Pain
Primary: Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale — -0.2; -0.5 units on a scale — p=0.38
Phase 2 N=83 Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
Prostate Cancer
Primary: PSA Slope (Trajectory) or the Change in PSA Level Over Time — 0.59; 0.27 ng/mL
N/A N=96 Vitamin D Repletion in Coronary Artery Disease
Vitamin D Deficiency · Coronary Artery Disease · Endothelial Dysfunction
Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index
Phase 3 N=130 Vitamin D in Vulnerable Adults (VIVA-VA)
Frail Elderly · Vitamin d Deficiency
Primary: Change in Short Physical Performance Battery Test Score — 7.3; 7.0 units on a scale
Phase 4 N=11 Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms
Myopathic Symptoms
Primary: Number of Participants With Reduction in Myopathic Pain — 4; 4 Participants
Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
N/A N=95 Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients
Cognitive Decline
Primary: 12-month Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) — 79.6; 82.1 units on a scale
Phase 3 N=85 Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women
Overweight · Obesity
Primary: Change in Body Fat Mass — -2.7; -0.4 kg — p=0.001
Phase 4 N=29 Vitamin D Repletion in Stone Formers With Hypercalciuria
Nephrolithiasis · Urolithiasis · Idiopathic Hypercalciuria
Primary: Change in 24 Hour Urine Calcium — 2 mg/day